Harvard's Wyss Institute licenses its eRapid technology to The iQ Group Global

(Wyss Institute for Biologically Inspired Engineering at Harvard) The Wyss Institute for Biologically Inspired Engineering at Harvard University announced that its eRapid technology has been licensed to The iQ Group Global for COVID-19 diagnostic applications. The Australian consortium will integrate the biomarker detection technology with its transistor technology to enable specific and sensitive SARS-CoV-2 testing in addressing the global diagnostic gap in the rampant coronavirus pandemic.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news